Journal article
Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy
Hepatology research, Vol.40(9), pp.870-877
Received 23 January 2010; revision 10 May 2010; accepted 21 May 2010.
09/2010
DOI: 10.1111/j.1872-034X.2010.00692.x
PMID: 20887591
Abstract
Aim: Hepatic steatosis is linked to development of hepatocellular carcinoma (HCC) in non-viral liver disease such as non-alcoholic steatohepatitis. The present study aimed to assess whether hepatic steatosis is associated with the development of HCC in chronic hepatitis C.
Methods: We studied a retrospective cohort of 1279 patients with chronic hepatitis C who received interferon (IFN) therapy between 1994 and 2005 at a single regional hospital in Japan. Of these patients, 393 had a sustained virological response (SVR) and 886 had non-SVR to IFN therapy. After IFN therapy, these patients were screened for development of HCC every 6 months. The average period of observation was 4.5 years.
Results: HCC developed in 68 patients. The annual incidence of HCC was 2.73% for patients with a steatosis grade of 10% or greater and 0.69% for patients with a steatosis grade of 0–9%. On multivariate analysis, higher grade of steatosis was a significant risk factor for HCC independent of older age, male sex, higher body mass index (BMI), advanced fibrosis stage and non-SVR to IFN therapy. The adjusted risk ratio of hepatic steatosis was 3.04 (confidence interval 1.82–5.06, P < 0.0001), which was higher than that of older age (1.09), male sex (2.12), non-SVR to IFN (2.43) and higher BMI (1.69).
Conclusion: Hepatic steatosis is a significant risk factor for development of HCC in chronic hepatitis C independent of other known risk factors, which suggest the possibility that amelioration of hepatic steatosis may prevent hepatocarcinogenesis.
Details
- Title: Subtitle
- Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy
- Creators
- Masayuki Kurosaki - Divisions of Gastroenterology and HepatologyTakanori Hosokawa - Divisions of Gastroenterology and HepatologyKotaro Matsunaga - Pathology, Musashino Red Cross Hospital, TokyoItsuko Hirayama - Divisions of Gastroenterology and HepatologyTomohiro Tanaka - Divisions of Gastroenterology and HepatologyMitsuaki Sato - Divisions of Gastroenterology and HepatologyYutaka Yasui - Divisions of Gastroenterology and HepatologyNobuharu Tamaki - Divisions of Gastroenterology and HepatologyKen Ueda - Divisions of Gastroenterology and HepatologyKaoru Tsuchiya - Divisions of Gastroenterology and HepatologyTeiji Kuzuya - Divisions of Gastroenterology and HepatologyHiroyuki Nakanishi - Divisions of Gastroenterology and HepatologyJune Itakura - Divisions of Gastroenterology and HepatologyYuka Takahashi - Divisions of Gastroenterology and HepatologyYasuhiro Asahina - Divisions of Gastroenterology and HepatologyNobuyuki Enomoto - First Department of Internal Medicine, University of Yamanashi, Yamanashi, JapanNamiki Izumi - Divisions of Gastroenterology and Hepatology
- Resource Type
- Journal article
- Publication Details
- Hepatology research, Vol.40(9), pp.870-877
- Edition
- Received 23 January 2010; revision 10 May 2010; accepted 21 May 2010.
- Publisher
- Blackwell Publishing Asia
- DOI
- 10.1111/j.1872-034X.2010.00692.x
- PMID
- 20887591
- ISSN
- 1386-6346
- eISSN
- 1872-034X
- Number of pages
- 8
- Language
- English
- Date published
- 09/2010
- Academic Unit
- Gastroenterology and Hepatology; Internal Medicine
- Record Identifier
- 9984094372702771
Metrics
8 Record Views